Compass Pathways said Tuesday that patients in the second of its two pivotal psilocybin trials maintained their response to treatment for at least six months, keeping the company on track to complete its NDA filing …
Source: Endpoints News
You may also like
Deals, deals, deals; Biohaven takes on Eli Lilly; and...
German lawmakers pass cost-saving bill that drugmakers...
This common pesticide may be quietly wiping out future...
Boehringer Ingelheim’s Jascayd approved by MHRA for...
Ipsen to acquire Memo Therapeutics in deal worth more...
Macrophage Membrane-Derived Nanoparticles Shows...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.